The use of antineuropathic medications for the treatment of chronic pain.
SNRI
chronic pain
gabapentinoids
neuropathic pain
treatment
tricyclic antidepressants
Journal
Best practice & research. Clinical anaesthesiology
ISSN: 1878-1608
Titre abrégé: Best Pract Res Clin Anaesthesiol
Pays: Netherlands
ID NLM: 101121446
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
16
07
2020
accepted:
03
08
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Chronic pain syndromes cost the US healthcare system over $600 billion per year. A subtype of chronic pain is neuropathic pain (NP), which is defined as "pain caused by a lesion or disease of the somatosensory system," according to the International Association for the Study of Pain (IASP). The pathophysiology of neuropathic pain is very complex, and more research needs to be done to find the exact mechanism. Patients that have preexisting conditions such as cancer and diabetes are at high-risk of developing NP. Many NP patients are misdiagnosed and receive delayed treatment due to a lack of a standardized classification system that allows clinicians to identify, understand, and utilize pain management in these patients. Medications like tricyclic antidepressants, serotonin-norepinephrine reuptake Inhibitor (SNRIs), and gabapentinoids are first-line treatments followed by opioids, cannabinoids, and other drugs. There are limited studies on the treatment of NP.
Identifiants
pubmed: 33004161
pii: S1521-6896(20)30075-6
doi: 10.1016/j.bpa.2020.08.007
pii:
doi:
Substances chimiques
Anticonvulsants
0
Antidepressive Agents, Tricyclic
0
Serotonin and Noradrenaline Reuptake Inhibitors
0
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-506Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicts of interest to disclose.